Identification of New Prognostic Factors of Pulmonary Hypertension

Circulation Journal - Tập 74 Số 9 - Trang 1965-1971 - 2010
Yutaka Miura1, Yoshihiro Fukumoto1, Koichiro Sugimura1, Minako Oikawa1, Makoto Nakano1, Shunsuke Tatebe1, Saori Miyamichi1, Kimio Satoh1, Hiroaki Shimokawa1
1Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1016/j.jacc.2009.04.011

10.1016/j.jacc.2009.04.012

10.1056/NEJMra040291

10.1016/j.jacc.2004.02.029

10.1161/CIRCULATIONAHA.104.503540

10.1620/tjem.211.309

7. Nagaya N, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Nakanishi N, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999; 160: 487-492.

8. Torbicki A, Kurzyna M, Kuca P, Fijalkowska A, Sikora J, Florczyk M, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003; 108: 844-848.

9. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.

10.1161/CIRCULATIONAHA.109.192230

11. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-870.

12. Machado RD, James V, Southwood M, Harrison RE, Atkinson C, Stewart S, et al. Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation 2005; 111: 607-613.

13. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): Results of a randomized trial. Ann Intern Med 1990; 112: 485-491.

10.1056/NEJMoa012212

10.1056/NEJMoa050010

16. Sasayama S, Kunieda T, Tomoike H, Matsuzaki M, Shirato K, Kuriyama T, et al. Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension. Circ J 2005; 69: 131-137.

10.1016/j.jacc.2009.04.017

18. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension: A national prospective study. Ann Intern Med 1987; 107: 216-223.

10.1253/circj.CJ-08-0181

10.1183/09031936.04.00051104

10.1183/09031936.04.00028404

10.1183/09031936.05.00075305

23. Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Ann Intern Med 2008; 149: 521-530.

24. Dimopoulos K, Inuzuka R, Goletto S, Giannakoulas G, Swan L, Wort SJ, et al. Improved survival among patients with eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010; 121: 20-25.

10.1161/01.RES.0000111804.34509.94

26. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005; 91: 391-392.

10.1097/01.fjc.0000248244.64430.4a

10.1097/FJC.0b013e31806befe6

10.1253/circj.CJ-09-0135

30. Silva DR, Gazzana MB, John AB, Siqueira DR, Maia AL, Barreto SS. Pulmonary arterial hypertension and thyroid disease. J Bras Pneumol 2009; 35: 179-185.

31. Satoh M, Aso K, Nakayama T, Naoi K, Ikehara S, Uchino Y, et al. Autoimmune thyroid disease in children and adolescents with idiopathic pulmonary arterial hypertension. Circ J 2010; 74: 371-374.

32. Nakchbandi IA, Wirth JA, Inzucchi SE. Pulmonary hypertension caused by Graves' thyrotoxicosis: Normal pulmonary hemodynamics restored by (131)I treatment. Chest 1999; 116: 1483-1485.

33. Danzi S, Klein I. Thyroid hormone and blood pressure regulation. Curr Hypertens Rep 2003; 5: 513-520.

10.1161/CIRCULATIONAHA.106.678326

35. Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scarlattini M, et al. Low-T3 syndrome: A strong prognostic predictor of death in patients with heart disease. Circulation 2003; 107: 708-713.

36. Pingitore A, Landi P, Taddei MC, Ripoli A, L'Abbate A, Iervasi G. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med 2005; 118: 132-136.

37. Iervasi G, Molinaro S, Landi P, Taddei MC, Galli E, Mariani F, et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 2007; 167: 1526-1532.

10.1016/S0735-1097(02)02012-0

39. Sandoval J, Bauerle O, Palomar A, Gomez A, Martinez-Guerra ML, Beltran M, et al. Survival in primary pulmonary hypertension: Validation of a prognostic equation. Circulation 1994; 89: 1733-1744.

40. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.

41. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.